News | February 05, 2022
IOL Chemicals and Pharmaceuticals Q3FY22 PAT at Rs. 40.07 crore
IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021
IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021
The audit is a PAI for two of its product applications filed from this facility
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
The company has 47 ANDA's pending approval with the U.S.FDA
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
It is the generic version of molnupiravir
It will be marketed under the brand name Molunamax
The cash consideration for the acquisition is US$ 18 million.
Subscribe To Our Newsletter & Stay Updated
